TP53 and ovarian carcinoma: Considering the major regulatory function of p53 on NOXA and Bax, two p53 and/or p73 downstream target genes, we further selected the p53 double deletion mutant SKOV3 cell line as a model of intrinsic resistance [15]–[17], and the p53-wild type A2780s cell line, which was derived from a untreated patient with primary ovarian carcinoma [17], [18], as a model of intrinsic chemosensitivity, to evaluate the effect of NOXA on the chemotherapeutic efficacy of cisplatin in A2780s and SKOV3 ovarian cancer models in vitro and in vivo.